文献速递慢性肾脏病

Klotho与内分泌型成纤维细胞生长因子:慢性肾脏病进展与心血管并发症的标志物?

Klotho and endocrine fibroblast growth factors: markers of chronic kidney disease progression and cardiovascular complications?
PubMed 文献 · Nephrol Dial Transplant · 2019-01-01

本文综述FGF19、FGF21、FGF23作为内分泌因子而非生长因子,其生理受体为FGFR与Klotho蛋白组成的二元复合物。FGF23和FGF21在CKD早期即升高,前者代偿性增加每肾单位磷排泄却诱导肾小管损伤并加速肾单位丢失,后者经中枢βKlotho-FGFR复合物激活应激反应;血中钙蛋白颗粒(CPP)与血管钙化/僵硬及死亡相关,提示其可能是心血管并发症的「病原体」。

要点

  • FGF23与FGF21在CKD早期即升高,可作为进展标志物。
  • FGF23代偿排磷但可致肾小管损伤并加速肾单位丢失。
  • CPP水平与CKD患者血管钙化/僵硬及死亡相关,或为心血管并发症病原。

核心结论

  • FGF21与FGF23不仅是CKD进展的生物标志物,还可能是加速CKD进展和加重心血管并发症的潜在致病因子。

主要发现

  • FGF23是骨源性排磷激素,结合肾小管αKlotho-FGFR复合物增加每肾单位磷排泄。
  • FGF23升高被认为代偿CKD进展中肾单位数量减少并维持磷平衡,但每肾单位磷排泄增加诱导肾小管损伤并加速肾单位丢失。
  • CKD进展伴血中钙蛋白颗粒(CPP)增加,CPP为钙磷纳米颗粒,能诱导内皮损伤和炎症反应。
  • 血清CPP水平与CKD患者血管钙化/僵硬及死亡相关,提示CPP可能是心血管并发症的「病原体」。
  • FGF21是肝源性激素,结合中枢神经系统βKlotho-FGFR复合物诱导应激反应,包括激活交感神经和下丘脑-垂体-肾上腺轴。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Three members of the fibroblast growth factor (FGF) family, FGF19, FGF21 and FGF23, are different from the other members in two major aspects. First, they are actually not growth factors but endocrine factors that regulate various metabolic processes. Second, their physiological receptors are not FGF receptors (FGFRs) but binary complexes of FGFRs and Klotho proteins. FGF23 and FGF21 have emerged as biomarkers that start increasing in early-stage chronic kidney disease (CKD). FGF23 is a bone-derived phosphaturic hormone that binds to the αKlotho-FGFR complex expressed in renal tubules to increase phosphate excretion per nephron. The FGF23 increase is deemed necessary to compensate for the decrease in the nephron number during CKD progression and to maintain the phosphate balance. However, the increase in phosphate excretion per nephron induces renal tubular damage and accelerates nephron loss. CKD progression is also associated with an increase in calciprotein particles (CPPs) in the blood. CPPs are calcium-phosphate nanoparticles with the ability to induce endothelial damage and inflammatory responses. The fact that serum CPP levels are correlated with vascular calcification/stiffness and mortality in CKD patients suggests that CPPs may serve as a 'pathogen' of cardiovascular complications. Like FGF23, FGF21 starts increasing in early-stage CKD. FGF21 is a liver-derived hormone that binds to the βKlotho-FGFR complex expressed in the central nervous system to induce stress responses, including activation of the sympathetic nervous system and the hypothalamus-pituitary-adrenal axis. Thus FGF21 and FGF23 are not merely biomarkers for CKD progression but potential pathogenic agents that accelerate CKD progression and aggravate cardiovascular complications.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Kuro-O M. Klotho and endocrine fibroblast growth factors: markers of chronic kidney disease progression and cardiovascular complications? Nephrol Dial Transplant. 2019. PMID: 29800324. doi:10.1093/ndt/gfy126

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。